留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

治疗心房纤颤和扑动的新药决奈达隆

吕娟丽 刘洋 李彦 刘振华

吕娟丽, 刘洋, 李彦, 刘振华. 治疗心房纤颤和扑动的新药决奈达隆[J]. 药学实践与服务, 2011, 29(1): 41-44.
引用本文: 吕娟丽, 刘洋, 李彦, 刘振华. 治疗心房纤颤和扑动的新药决奈达隆[J]. 药学实践与服务, 2011, 29(1): 41-44.
LV Juan-li, LIU Yang, Li Yan, Liu Zhen-hua. Dronedarone a new drug for atrial fibrillation or atrial flutter[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(1): 41-44.
Citation: LV Juan-li, LIU Yang, Li Yan, Liu Zhen-hua. Dronedarone a new drug for atrial fibrillation or atrial flutter[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(1): 41-44.

治疗心房纤颤和扑动的新药决奈达隆

Dronedarone a new drug for atrial fibrillation or atrial flutter

  • 摘要: 决奈达隆为胺碘酮的类似物,结构中不含碘,减少了碘所致的器官毒性,为新型的抗心律失常药。2009年7月1日获FDA批准,用于治疗心房纤颤或心房扑动的心脏病患者。本文通过对决奈达隆进行文献检索,对其药理作用、药动学、临床评价、药物相互作用、不良反应等方面进行了综述。
  • [1] Wattigney WA, Mensah GA, Croft JB. Increased atrial fibrillation mortality: United States.1980~1998[J]. Am J Epidemiol,2002,155(9):819.
    [2] Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization foratrial fibrillation in the United States, 1985 through 1999: implications for primary prevention[J]. Circulation ,2003,108(6):711.
    [3] Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial[J]. Lancet,2000, 356(9244):1789.
    [4] Wyse DG, Waldo AL, DiMarco JP,et al.Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation[J]. N Engl J Med, 2002,347(23):1825 .
    [5] Wegener FT, Ehrlich JR, Hohnloser SH. Dronedarone: an emerging agent with rhythm- and rate-controlling effects[J]. J Cardiovasc Electrophysiol.2006, 17(12):S17.
    [6] Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone[J]. Circulation, 1999,100(22):2276 .
    [7] Hodeige D, Heyndrickx JP, Chatelain P, et al. SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs[J]. Eur J Pharmacol,1995,279(1):25.
    [8] Guiraudou P, Pucheu SC, Gayraud R, et al. Involvement of nitric oxide in amiodarone and dronedarone-induced coronary vasodilatation in guinea pig heart[J].Eur J Pharmacol ,2004,496(1-3):119.
    [9] Celestino D, Medei E, Moro S,et al. Acute in vitro effects of dronedarone, an iodine-free derivative, and amiodarone, on the rabbit sinoatrial node automaticity: a comparative study[J]. J. Cardiovasc Pharmacol Ther,2007, 12(3): 248.
    [10] Sun W, Sarma JS, Singh BN. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone[J]. J Cardiovasc Pharmacol, 2002,39(5):677.
    [11] Varró A, Takács J, Németh M, et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone[J]. Br J Pharmacol,2001,133(5):625.
    [12] Chatelain P, Meysmans L, Mateazzi Jr, et al. Clinietm: Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the β-adrenoceptor and adenylate cyclase in rat heart[J]. Br J Pharmacol,1995 ,116(3):1949.
    [13] Pantos C, Mourouzis I, Delbruyere M, et al. Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and post ischemic performance of the isolated rat heart[J]. Eur J Pharmacol, 2002, 444(3):191.
    [14] Touboul P, Brugada J, Capucci A, et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study[J]. Eur Heart J ,2003, 24 (16): 1481
    [15] Singh BN, Connolly SJ, Crijns HJ,et al.EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter[J]. N Engl J Med, 2007,357(10): 987.
    [16] Davy JM, Herold M, Hoglund C, et al. ERATO Study Investigators. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and Safety of Dronedarone for the Control of Ventricular Rate During Atrial Fibrillation (ERATO) study[J]. Am. Heart J,2008,156(3):527.
    [17] KΦber L , TorpPedersen C , McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure[J]. N Engl J Med ,2008 ,358 (25) :2678.
    [18] Hohnloser SH, Crijns HJ, van Eickels M,et al.ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation[J]. N Engl J Med ,2009,360(7): 668.
    [19] Sanofi-Aventis. DIONYSOS study results showed the respective profiles of dronedarone and amiodarone [EB/OL]. (2008-12-23) http://en.sanofi-aventis.com/binaries/20081223_dionysos_fe_en_en_tcm28-23624.pdf.
    [20] Dale KM, White CM.Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter[J]. Ann Pharmacother,2007,41(4):599.
    [21] Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials[J]. Am J Cardiol ,2003, 91(6A):15D.
    [22] Patel PD, Bhuriya R, Patel DD,et al. Dronedarone for atrial fibrillation: a new therapeutic agent[J]. Vasc Health Risk Manag,2009,5:635.
    [23] Quaglino D, Ha HR, Duner E, et al. Effects of metabolites and analogs of amiodarone on alveolar macrophages: structure-activity relationship. Am J Physiol Lung Cell Mol Physiol, 2004,287(2):L438.
    [24] Van Beeren HC, Jong WM, Kaptein E,et al. Dronedarone acts as a selective inhibitor of 3,5,3'-triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence[J]. Endocrinology ,2003,144(2):552.
    [25] Zipes DP, Camm AJ, Borggrefe M,et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines[J]. Circulation. 2006 ,114(10):e385.
    [26] Tschuppert Y,Buclin T,Rothuizen LE,et al. Effect of dronedarone on renal function in healthy subjects[J].Br J Clin Pharmacol,2007,64(6): 785.
  • [1] 李婷, 时扣荣, 李智, 王子玉, 曹爱霖, 钱皎.  达比加群酯治疗老年非瓣膜性心房颤动的有效性和安全性评价 . 药学实践与服务, 2023, 41(9): 557-560. doi: 10.12206/j.issn.2097-2024.202207029
    [2] 恽芸蕾, 高守红, 樊成辉, 缪海均.  米格列奈钙片健康人体药动学研究 . 药学实践与服务, 2014, 32(1): 45-48. doi: 10.3969/j.issn.1006-0111.2014.01.011
    [3] 李蔚, 白莉莉.  药物引起的心律失常142例分析 . 药学实践与服务, 2004, (5): 308-309.
    [4] 王仁云.  抗真菌药与心血管药物的相互作用 . 药学实践与服务, 2002, (1): 52-55.
    [5] 吉俭, 蔡广, 邱健强, 黄艳平.  天门冬氨酸钾镁与比索洛尔联用治疗甲亢患者快速心房颤动 . 药学实践与服务, 2001, (1): 3-3.
    [6] 王期中, 李西河, 徐贯芬, 庞广礼.  L-赖氨酸-Sepharose 4B吸附纤溶酶原及纤溶酶 . 药学实践与服务, 1997, (2): 90-92.
    [7] 李蔚.  老药新用治疗心律失常 . 药学实践与服务, 1997, (6): 335-336.
    [8] 温宏伟, 张力新, 富伟.  心得安加异搏定引起严重心律失常1例 . 药学实践与服务, 1995, (6): 368-369.
    [9] 王爱华.  抗心律失常新药——瑞卡南 . 药学实践与服务, 1994, (2): 3-4.
    [10] 陈崇羔.  抗心律失常新药——依沙噻嗪 . 药学实践与服务, 1994, (2): 1-2.
    [11] 王敬东.  黄连素的新用途——抗心律失常 . 药学实践与服务, 1993, (2): 114-116.
    [12] 鱼爱和, 李万亥.  口服避孕药的药动学相互作用 . 药学实践与服务, 1992, (1): 59-62.
    [13] 马苏兰.  非洛地平的临床药动学 . 药学实践与服务, 1992, (3): 8-9.
    [14] 刘锡钧, 苏开仲.  环胞菌素的药动学参数 . 药学实践与服务, 1990, (2): 32-32.
    [15] 石振武, 张紫洞.  抗心率失常药 . 药学实践与服务, 1988, (4): 10-13.
    [16] 张望海.  心律平三天治疗患者药动学参数变化 . 药学实践与服务, 1988, (1): 49-49.
    [17] 口服抗心律失常药盐酸恩卡胺 . 药学实践与服务, 1988, (4): 36-36.
    [18] ReierM.J.  抗心律失常药:吡美诺 . 药学实践与服务, 1986, (3): 6-7.
    [19] JamesNickas.  三环类抗抑郁药的抗心律失常作用 . 药学实践与服务, 1984, (3): 18-20.
    [20] 李以欣, 王叔滋, 张紫洞.  心律失常的治疗 . 药学实践与服务, 1983, (3): 39-45.
  • 加载中
计量
  • 文章访问数:  2014
  • HTML全文浏览量:  224
  • PDF下载量:  110
  • 被引次数: 0
出版历程
  • 收稿日期:  2010-03-04
  • 修回日期:  2010-03-11

治疗心房纤颤和扑动的新药决奈达隆

摘要: 决奈达隆为胺碘酮的类似物,结构中不含碘,减少了碘所致的器官毒性,为新型的抗心律失常药。2009年7月1日获FDA批准,用于治疗心房纤颤或心房扑动的心脏病患者。本文通过对决奈达隆进行文献检索,对其药理作用、药动学、临床评价、药物相互作用、不良反应等方面进行了综述。

English Abstract

吕娟丽, 刘洋, 李彦, 刘振华. 治疗心房纤颤和扑动的新药决奈达隆[J]. 药学实践与服务, 2011, 29(1): 41-44.
引用本文: 吕娟丽, 刘洋, 李彦, 刘振华. 治疗心房纤颤和扑动的新药决奈达隆[J]. 药学实践与服务, 2011, 29(1): 41-44.
LV Juan-li, LIU Yang, Li Yan, Liu Zhen-hua. Dronedarone a new drug for atrial fibrillation or atrial flutter[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(1): 41-44.
Citation: LV Juan-li, LIU Yang, Li Yan, Liu Zhen-hua. Dronedarone a new drug for atrial fibrillation or atrial flutter[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(1): 41-44.
参考文献 (26)

目录

    /

    返回文章
    返回